How’s it Growing?
AIM at Melanoma is honored to have been selected by the Matthew Hill Foundation to be a benefitting charity in…
Blog - Melanoma360
11/16/2022
How’s it Growing?
AIM at Melanoma is honored to have been selected by the Matthew Hill Foundation to be a benefitting charity in…
|
11/16/2022
President’s Letter | November 2022
From the Desk of Samantha Guild November is the month to prioritize our gratitude, and I never tire of this…
|
11/16/2022
The Importance of Having a Will
It started with a 13-year melanoma survivor letting us know that he had put us in his will. Jeff Berg,…
|
11/16/2022
In Plain English: Tumor-Infiltrating Lymphocyte (“TIL”) Therapy for Advanced Melanoma
By Kim Margolin, M.D., FACP, FASCO Background—Immunotherapy of melanoma The explosion of immunotherapy over the past decade has revolutionized the…
|
11/11/2022
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
(November 07, 2022 08:01 ET | Source: Iovance Biotherapeutics, Inc. ) Clinically Meaningful and Durable Activity in Largest Cell Therapy…
|
|
11/08/2022
Living Beyond Melanoma: A Conversation with Stage IV Melanoma Survivor, Stephanie Bowen
In this episode, Melissa Wilson, PA-C, MPAS, AIM’s “Ask a Medical Expert” and host of the webinar series, “From the…
|
11/07/2022
Diagnosed with Melanoma as a Teenager Changed My Life’s Course
By Mara Klecker Madison Goff spent her early teenage years tanning in her family’s tanning bed or laying by the…
|
10/12/2022
Create a Legacy with AIM
October 17th – 23rd, 2022 is National Estate Planning Awareness Week Creating a legacy gift that supports melanoma research in…
|
10/11/2022
Talking to Your Care Team about Your Sexual Orientation and Gender Identity
While it may be an uncomfortable topic to bring up, sharing your sexual orientation and gender identity with your cancer…
|
09/30/2022
Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma
(Source:Georgetown University Medical Center) Originally published Sep 27, 2022, Medical Life Sciences Giving immunotherapy before targeted therapy improves survival in…
|
Recent Posts
Aug. 07, 2026
RP1 Approved: A Long Road to a New Option for Patients
Aug. 07, 2026
Patient Webinar: Understanding Your Second-Line Options
Aug. 06, 2026
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
Aug. 06, 2026
AIM at Melanoma President Samantha Guild Receives SITC’s 2026 Tara Withington Public Service Award
Aug. 03, 2026